CIBC Bancorp USA’s Roivant Sciences ROIV Stock Holding History

CIBC Bancorp USA’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$300K	Sell	8,467 -1,054	-11%	-$31.1K	﹤0.01%	1539
2026 Q1	$264K	Buy	+9,521	New	+$245K	﹤0.01%	1474

Other funds holding ROIV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Bancorp USA's ROIV Position: Q2 2026 in Review

CIBC Bancorp USA reduced its Roivant Sciences (ROIV) stake by 11% in Q2 2026, selling an estimated $31.1K and leaving 8,467 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

CIBC Bancorp USA first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. 464 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

CIBC Bancorp USA held 8,467 shares of Roivant Sciences worth $300K as of Q2 2026.
CIBC Bancorp USA sold 1,054 Roivant Sciences shares in Q2 2026, an estimated $31.1K.
Roivant Sciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1539 holding.
CIBC Bancorp USA first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
464 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.